Roivant Sciences' (ROIV) unit Priovant Therapeutics said Friday the phase 2 study of its experimental drug, brepocitinib, showed improvement in cutaneous sarcoidosis disease activity at higher doses, while another unit, Pulmovant, said it completed enrollment of about 120 patients in a phase 2 trial of its experimental drug, mosliciguat, for pulmonary hypertension linked to lung disease.

Priovant said patients taking 45 mg of the drug improved by 22.3 points on a key skin scoring system by week 16, compared with just 0.7 points for placebo.

All patients in the 45 mg group achieved meaningful improvement, and 62% reached near-clear skin, the company said, adding that 69% of the 45 mg patients reached clear or almost clear status, while no placebo patients did.

Priovant plans to start a phase 3 trial in 2026 after consulting the US Food and Drug Administration.

Meanwhile, Pulmovant said the enrollment was completed in under 12 months and is on track to report results in H2 2026, it added.